Rhea-AI Summary
Forma Therapeutics Holdings, Inc. (Nasdaq: FMTX) announced promising interim results from a Phase 2 trial of olutasidenib, a selective inhibitor for IDH1 mutation-related hematological malignancies. The trial showcased a 33.3% composite complete remission rate in relapsed/refractory acute myeloid leukemia patients. The favorable safety profile aligned with earlier Phase 1 data, with common adverse events including nausea and fatigue. The positive findings support advancing the drug's clinical development amid ongoing studies for IDH1m AML and other cancers.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.66%
Tags